{"id":90855,"date":"2026-11-12T15:07:00","date_gmt":"2026-11-12T15:07:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=90855"},"modified":"2026-11-13T02:13:08","modified_gmt":"2026-11-13T02:13:08","slug":"radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/","title":{"rendered":"Radiopharmaceuticals Market to Reach USD 15.21 Billion by 2035 as Radioligand Therapy Moves Earlier in Cancer Care and Curium\u2013Lantheus Reshapes the Competitive Map"},"content":{"rendered":"<p><em>North America Holds 43.95% of a USD 8.28 Billion Market, Diagnostics Lead and Therapeutics Grow Fastest: Precedence Research Segment, Company and Buyer Intelligence<\/em><\/p>\n<p>Ottawa, Nov.  12, 2026  (GLOBE NEWSWIRE) &#8212; <img decoding=\"async\" height=\"62.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/800c0ad9-1822-4e7c-961d-f8c95c43ab63\/image1.png\" width=\"190.0px\" data-dpi=\"96\" data-filename=\"image1.png\" \/><\/p>\n<p><i>The global radiopharmaceuticals market is valued at USD 8.28 billion in 2026, up from USD 7.51 billion in 2025, and is projected to reach USD 15.21 billion by 2035 at a CAGR of 7.31%. North America held 43.95% of 2025 revenue, and the U.S. market is expected to grow from USD 2.7 billion in 2025 to about USD 5.4 billion by 2035.<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"319.91px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/aeb91fe3-9f06-4766-8976-90b68e17297d\/image2.png\" width=\"568.75px\" data-dpi=\"72\" data-filename=\"image2.png\" \/><\/p>\n<p>Precedence Research today released updated intelligence on the global <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KC8hzLLQRvbamTorZh_GU0EmTEItdBjmHZ2VUwQ6mwBuDFNJ2HQ66LlythK-GcjUvmhPRlndiP4h8xI0IWGm5wat_onN_JNiCESVcrkWYTifWMijq_eCcQnjmrW4vuoHQ33B262XyrjoDt0DZX_iXopwMGWTntHZavIzx6sD2xI=\" rel=\"nofollow\" target=\"_blank\" title=\"radiopharmaceuticals market,\">radiopharmaceuticals market,<\/a> covering radioactive drugs used to image disease and to treat it, from technetium-99m heart and bone scans to PET tracers for prostate cancer and lutetium-177 radioligand therapies. The market is valued at USD 8.28 billion in 2026 and is forecast to reach USD 15.21 billion by 2035, adding USD 6.93 billion in annual revenue.<\/p>\n<p>The field is shifting from imaging toward treatment. Diagnostics still account for about 60% of revenue, but therapeutics are the fastest-growing type as radioligand therapies move into earlier stages of cancer. On July 31, 2026, the U.S. Food and Drug Administration approved Novartis&#8217;s Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer, nearly doubling the eligible patient population. Pluvicto sales reached USD 674 million in the third quarter of 2026, up 20%.<\/p>\n<p>The competitive map is also changing. Curium agreed in August 2026 to acquire Lantheus for up to about USD 8.0 billion, combining two of the largest suppliers, and in September the FDA approved Lantheus&#8217;s Bravnetsa, the first therapeutically equivalent version of Novartis&#8217;s Lutathera. Large drugmakers including Eli Lilly, AstraZeneca, Bristol Myers Squibb and Sanofi are building radiopharma pipelines. For developers, isotope producers, radiopharmacies, hospitals and investors, isotope supply, manufacturing and delivery logistics now decide who can scale.<\/p>\n<p><b>Full report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WavldOizdySs6KA0E7g8WUbmiSctP55gWZdMK7_cN-1brh-e0EkELaIvLYrKCfDuy_N-I6Vx8FEQ0yT1yTT3ydcI3PoUa5vTSCgY3pIW6gVU-xPlndUG--LrHeMnqUYoCk4HABJLtg3ijI6m1FBOzHLmvyo8-j4emf1VXRsU_rk5KJiOupQDnZrtlcz66oYRyjYMvnAdgV1PN2252mcJGQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/radiopharmaceuticals-market<\/a><\/p>\n<p><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WavldOizdySs6KA0E7g8WUbmiSctP55gWZdMK7_cN-1jE2YfHMbEH-_Ex8l6Ecr4NXM0nEMbm_tSItUDG_yMZ6goIFnuWwqdNQ5U-8nAQP3p6TCeOHYVVpUjaZzv_eQPbmUdt7R7_LY1b-3Gn0Jot9aD4yH4FYDmMyZ6LkaUlAA=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/sample\/3418<\/a><\/p>\n<p><b>Market Size and Growth<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Market Indicator<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"><b>Value<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Global market size, 2025<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 7.51 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Global market size, 2026<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 8.28 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Forecast market size, 2035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 15.21 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CAGR, 2026\u20132035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">7.31%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Absolute growth, 2026\u20132035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 6.93 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">U.S. market size, 2025 \u2192 2035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 2.7 billion \u2192 about USD 5.4 billion (7.18% CAGR)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest region, 2025<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">North America (43.95%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Fastest-growing region<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Asia Pacific<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Leading type \/ application<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Diagnostics (~60%) \/ oncology (~60%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Top 5 company share (estimated)<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">60\u201365%<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/e658e017-7218-4742-9b37-cfeb47894641\/image3.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image3.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 1: Radiopharmaceuticals Market Snapshot<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>Growth combines a large, steady diagnostic base with a faster-growing therapeutic layer. Therapy revenue per patient is far higher than imaging, so each new therapeutic approval adds more value than a new tracer.<\/p>\n<p><b>Segment Intelligence: Dominant and Fastest-Growing Segments<\/b><\/p>\n<p>2026 values below apply the approximate 2025 shares published by Precedence Research to the 2026 market size of USD 8.28 billion and are modeled estimates.<\/p>\n<p><b>Radiopharmaceuticals Market by Type and Application<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Segment<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Approx. 2025 Share<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>2026 Value (modeled)<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Growth Signal<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Diagnostics<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">~60%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 4.97 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest; SPECT and PET imaging<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Therapeutics<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">~40%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 3.31 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Fastest-growing type; radioligand therapy<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Oncology (application)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">~60%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 4.97 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest application<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Cardiology (application)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">~20%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 1.66 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Myocardial perfusion imaging<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Neurology, thyroid and others<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">~20%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 1.66 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Alzheimer&#8217;s and thyroid uses<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Radiopharmaceuticals Market: Leading and Fastest-Growing Segments<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Segment Group<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Leading Segment<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Fastest-Growing Segment<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Key Fact<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Radioisotope<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Technetium-99m<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Gallium-68<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Tc-99m supports about 80% of SPECT procedures<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Therapeutic isotope<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Lutetium-177<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Alpha emitters (actinium-225) in pipeline<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Lu-177 holds about 85% of therapeutic revenue<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Diagnostic modality<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">SPECT<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">PET<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">PET grows about 13% a year<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">End user<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hospitals &amp; clinics<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Specialty and imaging centers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Therapy needs nuclear medicine units<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Type.<\/b> Diagnostics lead because SPECT and PET scans are used every day in cardiology, oncology and neurology. Therapeutics grow fastest, led by lutetium-177 products such as Pluvicto and Lutathera, which together account for most therapy revenue.<\/p>\n<p><b>Radioisotope.<\/b> Technetium-99m remains the workhorse of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lopEl2JKO1hn5PW1fjLYbDYllsP0exFeFcv1lOXmJ9bKXoJFwdfjDMo0bLbugI_jNkXh7j9N-86REdNEiQbXWqN_2DRlpQLaibYX497Vks5Pj94ol6EW68V0tOEWtIFuPxBdtUPD684RxavBUBqORg==\" rel=\"nofollow\" target=\"_blank\" title=\"nuclear medicine\">nuclear medicine<\/a>. Gallium-68 grows fastest, driven by PSMA and somatostatin-receptor PET imaging that selects patients for radioligand therapy, a model known as theranostics.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Regional and Country Analysis<\/b><\/p>\n<p><b>Radiopharmaceuticals Market by Region<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Region<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"><b>Approx. 2025 Share<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"><b>Key Facts<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"><b>Growth Signal<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">North America<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">43.95%<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">U.S. USD 2.7B (2025) \u2192 about USD 5.4B (2035)<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">New therapy approvals; dense PET network<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Europe<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">~25%<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Strong nuclear medicine base; isotope reactors<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Theranostics adoption<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Asia Pacific<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">~22%<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Fastest-growing region<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">China approvals; new cyclotrons<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Rest of world<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">~8%<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Latin America, Middle East &amp; Africa<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Gradual access<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>North America.<\/b> The U.S. leads because new therapies launch there first and the PET imaging network is extensive. Novartis has five U.S. radioligand manufacturing sites operating or under construction and can deliver Pluvicto to treatment sites within five days, a sign of how logistics define competitiveness in this market.<\/p>\n<p><b>Europe.<\/b> Europe is the second-largest region, with a long nuclear medicine tradition and key isotope producers. New production capacity, such as PanTera&#8217;s actinium-225 project in Belgium, supports the next wave of alpha therapies.<\/p>\n<p><b>Asia Pacific.<\/b> Asia Pacific grows fastest. Novartis cited new approvals in China among the drivers of third-quarter 2026 Pluvicto growth, and Japan&#8217;s Nihon Medi-Physics and other regional suppliers are expanding diagnostic networks.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>What Is Changing in the Industry<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/6bb86d35-64f8-49d6-8f45-ab06b8b8cf38\/image4.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image4.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 2: Radiopharmaceutical Leaders, Latest Reported Signals<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Radioligand therapy is moving into earlier disease.<\/b> On July 31, 2026, the FDA approved Pluvicto with an androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer, based on the PSMAddition trial, which showed a 33% reduction in the risk of progression or death in an updated analysis. Novartis says the label now covers all stages of PSMA-positive metastatic prostate cancer.<\/p>\n<p><b>What it indicates:<\/b> Therapy volumes will rise sharply, increasing demand for lutetium-177, PSMA PET scans and treatment capacity in hospitals.<\/p>\n<p><b>Consolidation is creating a new major player.<\/b> On August 3, 2026, Curium agreed to acquire Lantheus in an all-cash deal worth up to about USD 8.0 billion, including contingent value rights. Lantheus reported third-quarter 2026 revenue of USD 389.9 million, including USD 238.9 million from its PSMA PET agent Pylarify.<\/p>\n<p><b>What it indicates:<\/b> The combined company will hold an estimated share close to Novartis, with a full range of diagnostics, therapeutics and isotope supply.<\/p>\n<p><b>Equivalent versions of therapies are arriving.<\/b> On September 22, 2026, the FDA approved Lantheus&#8217;s Bravnetsa (lutetium Lu 177 dotatate), the only radiopharmaceutical the agency has found therapeutically equivalent to Lutathera for certain neuroendocrine tumors. Lutathera generated USD 219 million in Novartis&#8217;s third quarter.<\/p>\n<p><b>What it indicates:<\/b> Price competition is reaching therapeutic radiopharmaceuticals, which will widen access but pressure margins for first-generation products.<\/p>\n<p><b>Big pharma is buying into the field.<\/b> Novartis acquired Mariana Oncology and licensed a preclinical radioligand asset from BoomRay Pharmaceuticals in 2026. Eli Lilly has a collaboration with AdvanCell, AstraZeneca acquired Fusion Pharmaceuticals and Bristol Myers Squibb owns RayzeBio.<\/p>\n<p><b>What it indicates:<\/b> Pipelines are shifting toward alpha emitters such as actinium-225 and new targets beyond PSMA and somatostatin receptors.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Key Market Drivers<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Rising cancer incidence and demand for targeted <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lIi96pakW2Fvfjhq43EGDEC2gg7SfBiugTfbcdkKSahAni1QkqFQxa1P9vu0XNtHQuohK1eYX2zUIE58Uej-wljTLOV3nHgNoggPkVqSOl8_-MAMfzpnyKQ5u3P5DoFJOoUVAkt7QmamEpbvU0W4UQ==\" rel=\"nofollow\" target=\"_blank\" title=\"cancer therapeutics\">cancer therapeutics<\/a>.<\/li>\n<li style=\"margin-bottom:4pt;\">Theranostics, which pairs PET imaging with matched therapy to select patients.<\/li>\n<li style=\"margin-bottom:4pt;\">Label expansions that move radioligand therapy into earlier lines.<\/li>\n<li style=\"margin-bottom:4pt;\">Growth of PET imaging in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lIi96pakW2Fvfjhq43EGDGoptYTkyscpn3vtTC5I5icNiE3m1xnOFw5Z8g8FFMk5ljzhFrnNx7shkYQn4MRi52ZXfriBLD0jCF3P2hM5zMZkzKX9LRyzU84pqbD8FTIuUHbnD5AW4HdhSXk-X2Oh6w==\" rel=\"nofollow\" target=\"_blank\" title=\"cancer diagnostics\">cancer diagnostics<\/a>, cardiology and neurology.<\/li>\n<li style=\"margin-bottom:4pt;\">Large pharma investment through acquisitions and licensing.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Major Challenges<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Limited and fragile isotope supply, especially actinium-225 and molybdenum-99.<\/li>\n<li style=\"margin-bottom:4pt;\">Short half-lives that require fast, tightly scheduled manufacturing and delivery.<\/li>\n<li style=\"margin-bottom:4pt;\">Shortage of nuclear medicine staff and treatment rooms in hospitals.<\/li>\n<li style=\"margin-bottom:4pt;\">Radiation safety regulation and waste handling costs.<\/li>\n<li style=\"margin-bottom:4pt;\">New equivalent products that bring price competition.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Emerging Opportunities<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Alpha-emitter therapies<\/b> built on actinium-225 and lead-212.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Gallium-68 and PET diagnostics<\/b>, the fastest-growing isotope and modality.<\/li>\n<li style=\"margin-bottom:4pt;\">Isotope production and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Qa_IriZsl8pv0kje2PLF9e08aJ3LBXi7wPa_KKpmkawaQm0WJFVl6xY4SsKxnJp3rzLlyltCzMVYS7lq86v_eBwWYW0CqbN7Odq8nUP2SDyu1Jv_QKCVj7b7BU39BYxsjfZA99xf7rZ6mLm_4lJVrA==\" rel=\"nofollow\" target=\"_blank\" title=\"radiopharmaceutical CDMO\">radiopharmaceutical CDMO<\/a> services to relieve supply limits.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Asia Pacific expansion<\/b>, the fastest-growing region.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>New targets<\/b> such as FAP, GRPR and CA9 beyond prostate and neuroendocrine cancers.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Company and Competitive Intelligence<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/010e4cc8-bf8d-4031-9b84-f3caaaa06465\/image5.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image5.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 3: Radiopharmaceuticals Estimated Company Shares<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>The market is concentrated. Precedence Research estimates that Novartis holds 28\u201330%, Lantheus 15\u201317%, Curium 12\u201314%, GE HealthCare 6\u20138% and Bayer 4\u20135%, with the top five holding 60\u201365% and the top ten 78\u201380%. Other key players include Cardinal Health, Telix, Jubilant Radiopharma, Eckert &amp; Ziegler, Bracco, Siemens Healthineers (PETNET), ITM, Eli Lilly, Bristol Myers Squibb, AstraZeneca, Orano Med, NorthStar, SHINE, Nordion, Clarity, Perspective Therapeutics and Nihon Medi-Physics.<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Company<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Est. Share<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Key Products \/ Focus<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Relevant Development<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Novartis<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">28\u201330%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pluvicto, Lutathera, Locametz<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pluvicto mHSPC approval (Jul 2026); Q3 Pluvicto sales USD 674M<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Lantheus<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">15\u201317%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pylarify, Definity, Bravnetsa<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">To be acquired by Curium (up to ~USD 8.0B); Bravnetsa approved Sep 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Curium<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">12\u201314%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">SPECT and PET agents, isotopes<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Agreed to acquire Lantheus (Aug 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">GE HealthCare<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">6\u20138%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Diagnostic tracers and imaging<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Integrated scanners and tracers<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Bayer<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">4\u20135%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Xofigo and pipeline<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Alpha therapy experience<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Telix \/ Clarity \/ ITM<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Smaller<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Theranostics developers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Named key players in the report<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Eli Lilly \/ AstraZeneca \/ BMS<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Entrants<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Alpha and beta therapy pipelines<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">AdvanCell, Fusion and RayzeBio programs<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Customer and Buyer Intelligence<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Target Account Group<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Decision-Makers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Purchase Signals<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Commercial Opportunity<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hospitals and cancer centers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Nuclear Medicine Director, Oncology Head<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">New approvals, therapy room expansions<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Radioligand therapy programs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Imaging centers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Operations Director, Radiology Lead<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">PET scanner purchases, PSMA demand<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">PET tracer supply contracts<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pharma developers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">BD Head, CMC Director<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pipeline entry, isotope needs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Isotope supply and CDMO services<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Radiopharmacies and distributors<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Network Director<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">New products, regional expansion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Dose distribution partnerships<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Payers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Medical Director, HTA Lead<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Label expansions, equivalents<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Value-based therapy coverage<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>How Precedence Research Supports Decision-Making<\/b><\/p>\n<p><b>Master Dataset<\/b> provides segment, regional and company data for radiopharmaceuticals and adjacent markets such as the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t9YraRBh3b2MsXMV1aMPugIqwaivgT89idW4mgL-W77Vt4MDX2OSlCgaLHKbpiBIO15T4NB4snkFWqE2Ezju___bN6QbNOLPQiX5WIpGiKS81_D3XGOfaRawaZaJ2vE2HQ5SWtXUdG9Z-1ySXW3mug==\" rel=\"nofollow\" target=\"_blank\" title=\"medical isotopes\">medical isotopes<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lopEl2JKO1hn5PW1fjLYbH7HSANTyiraj_I8MmWiCai5NGmIr-lMBW-j1b-qhOp0w0seD4gs8pLu9TRFq49d5LU7N47oTnZJ1696YyFBPXWgFXQyv94FnlavaRbYXz9IDRNgWij5YARpOdBkWsBp9Q==\" rel=\"nofollow\" target=\"_blank\" title=\"nuclear medicine\">nuclear medicine<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OWs5DqXQWAsBu_kIRdKbH47_ikCo6V1ZPx3uWO7Ctn-5B-Aj2UQ6zoZyPzTNhRlQyxClYuKGVU4k1bZ8p_Z_kidVT1Zh67CPQ25S8zy2Ttd7UHkphhkUeaYdW3LOXJ3F\" rel=\"nofollow\" target=\"_blank\" title=\"oncology\">oncology<\/a> markets. It helps teams size demand by isotope, modality and application.<\/p>\n<p><b>Precedence Quadrant<\/b> compares radiopharma companies on products, pipeline, isotope access and manufacturing reach, helping partners and investors screen leaders.<\/p>\n<p><b>Interactive Intelligence Dashboard<\/b> tracks approvals, equivalents, acquisitions and isotope capacity news, so teams can respond quickly.<\/p>\n<p><b>Quality &amp; Manufacturing Intelligence<\/b> maps isotope reactors, cyclotrons, radiopharmacies and CDMO capacity, supporting supply and site decisions.<\/p>\n<p><b>Customized Research<\/b> answers specific questions, such as actinium-225 supply outlook, theranostics adoption by country or the impact of the Curium\u2013Lantheus deal.<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Solution<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>What It Provides<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>How It Helps<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Master Dataset<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Segment, region and company data on radiopharmaceuticals<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Sizes demand by isotope and application<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Precedence Quadrant<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Company comparison on products and isotope access<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Screens partners and leaders<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Interactive Dashboard<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Live tracking of approvals, deals and capacity<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Times launch and investment decisions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Quality &amp; Manufacturing Intelligence<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Isotope, cyclotron and CDMO mapping<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Supports supply and site choices<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Customized Research<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Isotope, adoption and deal-impact studies<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Answers decision-specific questions<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Why Continuously Updated Intelligence Matters<\/b><\/p>\n<p>Radiopharmaceutical approvals, isotope supply events and deals now arrive every month. Monthly updates suit commercial and supply teams tracking approvals and isotope availability. Quarterly updates match company sales of Pluvicto, Lutathera and Pylarify. Six-monthly updates help strategy teams follow label expansions and new equivalents, and annual updates support investors reviewing market size and share. Precedence Research offers all four update cycles.<\/p>\n<p><b>Strategic Outlook<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>CEOs and CXOs:<\/b> the market nearly doubles to USD 15.21 billion by 2035; therapeutics will drive most new value.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Strategy and business development teams:<\/b> the Curium\u2013Lantheus deal resets competition; mid-sized developers are likely targets.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>R&amp;D leaders:<\/b> alpha emitters and new targets offer differentiation as lutetium-177 products face equivalents.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Procurement and supply teams:<\/b> secure lutetium-177, gallium-68 and actinium-225 contracts early.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Investors:<\/b> isotope production and radiopharmacy networks are strategic assets as therapy volumes grow.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Hospitals:<\/b> expanding Pluvicto eligibility requires more treatment rooms, staff and PET capacity.<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Company Ecosystem<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"446.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/4d378345-2165-4037-b1a1-1ffc9dd7173e\/image6.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image6.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 4: Radiopharmaceuticals Company Ecosystem, 2026<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Call to Action<\/b><\/p>\n<p>To understand which isotopes, therapies and companies will lead radiopharmaceuticals through 2035, explore the full report or speak with a Precedence Research analyst.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNnAswi9D4OiUrScyF7tlLG-RkDP1med57xu95MYub41cVKmmeQ5cvTvOKjhVb6DDiurANVqQsG1Wxcn8NohITJ3ELkNgy6M0hTijVO0x89SnLCyYnqEiR-9xETb2aDEPIorwyX3WV_nZUhQsl7gZzLJFuxhhfda1Th06eTPOmwKcQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/radiopharmaceuticals-market<\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNmEP7D_SwTVoUm175JwpusLMHCy4HtuqgZvvacNCtFnQS9fQy9Bk6nFQT_MVFBQCIT8WFL-N7YfikglTRY6pP7yi4V4ZHskoflnQCj9cOxtrwH1ouMS2gn3T9UZwtb_ToE=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/sample\/3418<\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Schedule a meeting:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNlL_zttNrm7i8jCmADzmIlnnStb3VigT5gV2PMnOo68IkWL51ntb-C7et7qJNeBQ7gyrsKGsGrLgF9fwR12F4Ie73JNvfaxs8ZuYyKFyetxGhlg1A2aEhhvabDkNogyzWk=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/schedule-meeting<\/a>\n<\/li>\n<\/ul>\n<p><b>Fill out the form for relevant samples, case studies, and examples.<\/b> sales@precedenceresearch.com<\/p>\n<p><b>Related Reports<\/b><\/p>\n<ol style=\"list-style-type:decimal;\">\n<li style=\"margin-bottom:3pt;\">Nuclear Medicine Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNnCFOROm29WmYUne8nr9dgKy8oLfPCtLSl2UhhJarqaHAT6PdZu2WXF6hAjQYNRxXY3dZJENZSXrh6LvC_2Nmo4sfAu1Hvi84gOO40Heuvn6NHmIT_CUQu-SCJZXQZrfVQ7XiRPHeVJk6F_D2aCE2xn\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/nuclear-medicine-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Medical Isotopes Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNkcP_umpGV9mB0VfbXx5NDfEiS03ER3MLUP-z896WPQNh85xeY8Rz8Bpki4B2uBr6zWUYBtWMOqpuBHsTv3ZVltF8ThuDGRL_xofgwgaOVIrphQyygOhcTSEUhWd649wosduR9vpYAz5ipSwW_yB5OV\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/medical-isotopes-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Radiopharmaceutical CDMO Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNnAswi9D4OiUrScyF7tlLG-RkDP1med57xu95MYub41cdKhXP-6vLamjK7Vw6HbXXlUF-zfE_2MJKSxdoZ6EvvSDpEmusv0bwxs2Hu06HGkPtC2hsv-VtH5VfsjfnsdDJKDdlogVSa-sKMOA3EAh9_41YmqO_-Ilx4XwZ5JJT1EAQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/radiopharmaceutical-cdmo-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Oncology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNkfqDmQobZCGE-aj6doKixYh635H_4kbdV7M8l0pp2rW6_MbtfP_wAHCn3UoHF2yv7o1djCnxJqAmU2WJPq_rV62ah9pO8DXc-r9oM2qzQ8xtoKmkCuZTYCB0-1s65R78c=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/oncology-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Cancer Diagnostics Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNkhSUWbRGhdVPKeBsL5y8NCPPTtIamIvSxf2Y7oVRdQFicPS8DmrgRezMGFH5i4dWSiO0TM3Gri0Q_Vm4ShK7aNhf_qVV_2weXh9YS0XATcbFXVwtNJBrJOLYROAZ-wwsYzeT8u3fh5fBkmXrFiobMX\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cancer-diagnostics-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Cancer Therapeutics Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNkhSUWbRGhdVPKeBsL5y8NCqCi_Rt4fHuLTo9L9TEMrdEyK7ELvO6ITGWrtDW0-fAOLNvCOxKsZ6j2UD36mRvaKekunybEBPSIpfZU1ZaztG9HiJe1N3qbcgto-6gohp7PH43rOvhwru3Ep0feJiVgiSutjy5dye9ygTYkRwVf4mQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cancer-therapeutics-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Cancer Drugs Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNkhSUWbRGhdVPKeBsL5y8NCjF6oNgb0rQv-oGGBCyMU2mT3uaUUIH3m_uv5LAO2W6P9v7N2YXrZxdWRfJh9vZ7-wbOcH_PaorOdJMAq4gVvxYnp-kZdlhvr21Y45uqEkKPx1bmSjknzJW7vnsArQFLU\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cancer-drugs-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Precision Medicine Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNkie3VFNxjMximOu3-h3BZJ9xFOLQi07g55J5_838VOfDG0hlnWN1OuHU_6XTx_3CmvlFxZBUytmKUilh2Biu9tVfWn4SXLkBete0ehEr-y9NptZj8hhOR3ZiD2ZInmQoCwGhFufrh7Ok1EGdnZA97a\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/precision-medicine-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Oncology Molecular Diagnostic Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNkfqDmQobZCGE-aj6doKixYwB7hT_wXckwfQykH-jiyxxCLk8VZPqSv-jryQ4JTTiR4MKxO7XOJGqexEQPh-NKYVjX1s8sNm_BCrycikzZurZd35X_Ri9Ph0DMGoybBDfe-a48OqFAp7Xz4_UiBo9kgMPE8eRjT8-wxTBSYmElvx47GjhGqsychkWCr5INDeks=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/oncology-molecular-diagnostic-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Artificial Intelligence in Oncology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNmEAQ7W4pIW_N_r2NgZbKsqCAO4aJ8oB8ib-3G_nLyMbY3EH45s0e3GjBwNYnP9Dwh03inMJ4tU63oMCthdqNmP8os6htZlTNPmiEptR3fRmQI22m4q6UkcSV-VJ9MsaZq0Jld2_OL4yB2lcOoIF28_vglCOn1gYhnAYNX2pcG1pHGp-JYkXTwLlWx2S9-LMZJJ70y_twRUQfKmpIZpevDA\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/artificial-intelligence-in-oncology-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Antibody Drug Conjugates Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNmFsPCKdy00_SsUiW4E1MYjwqINEsxrb9_qopd-PQUGVtO2xrKC4W6dXfMlnvbA_Ljkc21ZAzAEH_A7vYaVbueSJHZ4rZb_aWgg8DMtAptUM3CYjzsACMp2k8CwZ7UmhLeFaAe9rAA_sTSNMj4iGNXOjShjaG6WkZuDJm0m4GvCqQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/antibody-drug-conjugates-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Monoclonal Antibodies Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNl5PA0AxoLZVNXKdM-g3GVQsHV0t0Oj1HXO1mCmHZr6OtA5nXrWFHTN18F7ewJAUwiLiAjp4qP8gVr_NfRp9dS8USPMjmwZDu7j1BEqRSo9_Qld3vkTugzXtO4c6C88IoMQZICWptMnW60SV973KynvddqQit6wwPzpb1FV7VH38g==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/monoclonal-antibodies-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Chemotherapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNlrUFy35Vy-OnVMFEjTtaugLdU4QogglA2VfVHP2tGXyRo-4x_I3SuVmnVaEs7n4SiCzhX4xozTyXX3RXGaE6EdtZrw-9GiqIZuwgMr77HQxpxVwOpfq2MR6sy0mpyY1h_GA8m9l1TZ78b_CtlOIFN4\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/chemotherapy-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Clinical Trials Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNnWiYKAFhuhdDBmqrNT6peq5_XJYSFh-W2SeJheIZpXHPX0pBmdlE1gT4t28O7XzVNAIvdABK-blQDpSGwDemC91q8Fc9Mgrz8nuSZ_OUKCca3z1AvKSuAkFuipQH0zUCsOiAUtLeFNyRYbd0SASteN\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/clinical-trials-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Pharmaceutical Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNm-qJLGckd3x9q-p8uOmYE5YUG5GwYmNlwNtUbUj2trMyjMTwszSX_tGl54C_ennEcFC9zLNsL0DcA2u2zhzhMOxb3Qh18O_sNM1U17-eNJpHh85gHTpwLowhTQQo-eKtGeV46W-bjjs4Rlzqnk0Lgz\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmaceutical-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Biopharmaceutical Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNnypePhqfiZHqR9qSXAN0C7E4-s6rH25jFtjiFK0F8Gj9yHmpLOwIBgnkZ8IfrsKxLgnP3pKj4xLseCxadR1uA2kyw3NBBPKlwhLKWPrcGf2t4NfzEmbJGZhQkgqgJnXMwGRDstMJT7LV18kbd4_EtI\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/biopharmaceutical-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Biotechnology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNnypePhqfiZHqR9qSXAN0C7Uiv-Wa-sR-OU1Ftta_qztQCives9hJIk2gcxn-202RR6UXEGrjdhq-TWE0a4hYuQ1C54iX7YpVc4pL13hFxTrYp8R-_ZcP-oHciIOBvtot0dQHrb0lM-TEmVJdTU2FNu\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/biotechnology-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Healthcare Analytics Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNk18cNQpZFoP6OURIgPzbQSp0Fs6ijh9f-GD6eN1Vdp4hHpp1qPGWMk2YWwGuZxdGs3mAf0EUb1M2b__OuYhbNZZpDfAvhZeU4fMk5K1ZWNr_wN2rhgrat288V3-UU4_WLqlRjXKk6k565yfLD1WrQ5fyzGRDT9tFZ7XRZmnyZKig==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/healthcare-analytics-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Healthcare IT Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNk18cNQpZFoP6OURIgPzbQSQepi4abrHb5oESRbuQK2C_3AKtF2A2HtpzciTZLPFzbVYC9ftwC8J5ywCfvEiiRUSZRWKJyabcyBjtgHPkZUKG-YJsZ2pfKx0fnTCmoSX5oW_pLN5nGIcFqKTPFxjqVt\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/healthcare-it-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Digital Health Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGxvpXkujah-XuUKY5TxTNnGYsEfzO2BjcDkuvgOizKJxLDoXsYN_W7hiIu09-jgOpcycHxj1q8dJ_XjZjHelBduNUMUE4G5_TvgP4ItBhcgI6EVuEJU67_8iKI-fVGWzssPh0oy2YkeLslPuTFsI00H8wZkzSr7Nezpo4EBn_ht\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/digital-health-market<\/a><\/li>\n<\/ol>\n<p><b>About Precedence Research<\/b><\/p>\n<p>Precedence Research is a global market intelligence and consulting company. It provides market sizing and forecasts, competitive and company analysis, customer and buyer intelligence and customized research across healthcare, pharmaceuticals, medical devices, ICT, energy, chemicals and materials and other industries, helping executives and investors make evidence-based decisions.<\/p>\n<p><b>Our Partners<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Towards Healthcare: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOD1DsnJ6G-zG8U55MyXVcOLrBkNLSr_n6gg4ct9wIsNT6i7Xlb141hQz9YRESONpSUzN90sbCWsmjDzg4UaWbQNxbRClrXX4Ov-oLf9L-MML\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardshealthcare.com\/<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Packaging: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOMMwaWEyze0A3svzCHANdA2fJBJluZRcYCsxz8m72eQwf1e4HOvmVcQoHu7wj1ZrNgUAPX-9B8XfkUTQdEq9YWmUNLkeTBRYT-_vIgQPzXp5\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardspackaging.com\/<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Chemical &amp; Materials: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOGXhLxnfSpt2TvUgFXvpA0vD1KGgCf7SqKs-1TIjOgg_ZsJ62-G-pLBE_ZkLA9WuUb7HQWqTczTm_kZ51b7pDAhjeI-095fIM-8vxY33wva9foyLyPpIvNJMdvbHvZFz1Q==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardschemandmaterials.com\/<\/a>\n<\/li>\n<\/ul>\n<p><b>Connect With Us<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">USA: +1 804 441 9344<\/li>\n<li style=\"margin-bottom:4pt;\">APAC: +61 485 981 310 or +91 87933 22019<\/li>\n<li style=\"margin-bottom:4pt;\">Singapore: +65 3105 1271<\/li>\n<li style=\"margin-bottom:4pt;\">Europe: +44 7383 092 044<\/li>\n<li style=\"margin-bottom:4pt;\">Email: sales@precedenceresearch.com\n<\/li>\n<\/ul>\n<p><b>Social Media<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOAeWIShJLkdtGavLJByiu0bToOXTnDCUABQSlWtgr9uPFmQ_GBU7ftJY-Ma_mFf3Qx8PC2J72_h9UBKRaZ8i-r0Nj58FbWVa6pmgR5E8Z9lvNIbboHjpredQgmJVlLYdQmIFbueM8cpE2iDDb1PYLAY=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.linkedin.com\/company\/precedence-research<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Facebook: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOJNHwmXtJtSyzgrIFmVCB6_fT-kh_MIg3LjK3gPtet3k0b62iOo35Z6rTRW21TviXwoo2CDw2Xo3tMvwkR1FspR0vNue1C-yiUXVLOgU3mwb4UHMwGgQWyJt9ubsQK1s8w==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.facebook.com\/precedenceresearch<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">X: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPOH587xfwTliDhhkwMEo3bqJVd80KTCJ4EFYKTAorRsue9Ob_n7RTPWqq2ejHXFEa6MbbyTodJtzb2hXRJLQK_1o=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/x.com\/precedence_r<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Medium: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zZLEBBmdGR_foND4fnBPONVjIVxuTszCl7XiJIypHZpwqLkvv3eB8-O8SslvYfS7_veZn7d-vQ2rdNA0NaHgKuSproKhH1U4oS1WBKERYWXNi_5iI5-Fde11Xgp9ZpT2RRbld16Tc9ysY_zdn1RxTw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/precedence-research.medium.com\/<\/a><\/li>\n<\/ul>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/MzEzMTRhMjEtOWU3My00ZGNiLTkyNjctODRkZmYwYmE4MjY2LTEyMTM4NDktMjAyNi0xMS0xMi1lbg==\/tiny\/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>North America Holds 43.95% of a USD 8.28 Billion Market, Diagnostics Lead and Therapeutics Grow Fastest: Precedence Research Segment, Company and Buyer Intelligence Ottawa, Nov. 12, 2026 (GLOBE NEWSWIRE) &#8212; The global radiopharmaceuticals market is valued at USD 8.28 billion in 2026, up from USD 7.51 billion in 2025, and is projected to reach USD [&#8230;]\n","protected":false},"author":1,"featured_media":90856,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-90855","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Radiopharmaceuticals Market to Reach USD 15.21 Billion by 2035 as Radioligand Therapy Moves Earlier in Cancer Care and Curium\u2013Lantheus Reshapes the Competitive Map - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Radiopharmaceuticals Market to Reach USD 15.21 Billion by 2035 as Radioligand Therapy Moves Earlier in Cancer Care and Curium\u2013Lantheus Reshapes the Competitive Map\" \/>\n<meta property=\"og:description\" content=\"North America Holds 43.95% of a USD 8.28 Billion Market, Diagnostics Lead and Therapeutics Grow Fastest: Precedence Research Segment, Company and Buye\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-12T15:07:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-13T02:13:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map.png\" \/>\n\t<meta property=\"og:image:width\" content=\"237\" \/>\n\t<meta property=\"og:image:height\" content=\"77\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Radiopharmaceuticals Market to Reach USD 15.21 Billion by 2035 as Radioligand Therapy Moves Earlier in Cancer Care and Curium\u2013Lantheus Reshapes the Competitive Map\",\"datePublished\":\"2026-11-12T15:07:00+00:00\",\"dateModified\":\"2026-11-13T02:13:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/\"},\"wordCount\":2364,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/\",\"name\":\"Radiopharmaceuticals Market to Reach USD 15.21 Billion by 2035 as Radioligand Therapy Moves Earlier in Cancer Care and Curium\u2013Lantheus Reshapes the Competitive Map - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-11-12T15:07:00+00:00\",\"dateModified\":\"2026-11-13T02:13:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Radiopharmaceuticals Market to Reach USD 15.21 Billion by 2035 as Radioligand Therapy Moves Earlier in Cancer Care and Curium\u2013Lantheus Reshapes the Competitive Map\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Radiopharmaceuticals Market to Reach USD 15.21 Billion by 2035 as Radioligand Therapy Moves Earlier in Cancer Care and Curium\u2013Lantheus Reshapes the Competitive Map - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/","og_locale":"en_US","og_type":"article","og_title":"Radiopharmaceuticals Market to Reach USD 15.21 Billion by 2035 as Radioligand Therapy Moves Earlier in Cancer Care and Curium\u2013Lantheus Reshapes the Competitive Map","og_description":"North America Holds 43.95% of a USD 8.28 Billion Market, Diagnostics Lead and Therapeutics Grow Fastest: Precedence Research Segment, Company and Buye","og_url":"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-11-12T15:07:00+00:00","article_modified_time":"2026-11-13T02:13:08+00:00","og_image":[{"width":237,"height":77,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Radiopharmaceuticals Market to Reach USD 15.21 Billion by 2035 as Radioligand Therapy Moves Earlier in Cancer Care and Curium\u2013Lantheus Reshapes the Competitive Map","datePublished":"2026-11-12T15:07:00+00:00","dateModified":"2026-11-13T02:13:08+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/"},"wordCount":2364,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/","url":"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/","name":"Radiopharmaceuticals Market to Reach USD 15.21 Billion by 2035 as Radioligand Therapy Moves Earlier in Cancer Care and Curium\u2013Lantheus Reshapes the Competitive Map - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-11-12T15:07:00+00:00","dateModified":"2026-11-13T02:13:08+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/radiopharmaceuticals-market-to-reach-usd-15-21-billion-by-2035-as-radioligand-therapy-moves-earlier-in-cancer-care-and-curium-lantheus-reshapes-the-competitive-map\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Radiopharmaceuticals Market to Reach USD 15.21 Billion by 2035 as Radioligand Therapy Moves Earlier in Cancer Care and Curium\u2013Lantheus Reshapes the Competitive Map"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=90855"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90855\/revisions"}],"predecessor-version":[{"id":90857,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/90855\/revisions\/90857"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/90856"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=90855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=90855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=90855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}